Adelaida Mayeta Peart
Nurse Practitioner · Conyers, GANPI 1881211233
Payments from drug & device makers
Across 136 payments — averaging $19.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$451
- AstraZeneca$428
- Novo Nordisk$394
- Amgen$316
- Shield Therapeutics Inc$141
- AbbVie$126
- plus $863 from 18 others
What the payments were for
- Food & beverage$2,718100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 24 | $451 |
| AstraZeneca | 22 | $428 |
| Novo Nordisk | 15 | $394 |
| Amgen | 19 | $316 |
| Shield Therapeutics Inc | 7 | $141 |
| AbbVie | 6 | $126 |
| Pfizer | 6 | $119 |
| Bayer | 6 | $115 |
| Sanofi-aventis U.S. LLC | 5 | $104 |
| Actelion Pharmaceuticals US, Inc. | 3 | $60 |
| Exact Sciences | 4 | $59 |
| Boston Scientific | 2 | $57 |
| GSK | 3 | $54 |
| Boehringer Ingelheim | 2 | $54 |
| Esperion Therapeutics, Inc. | 2 | $47 |
| Xeris Pharmaceuticals, Inc. | 2 | $37 |
| Corcept Therapeutics | 1 | $24 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $24 |
| Merck | 1 | $20 |
| Inspire Medical Systems, Inc. | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Astellas Pharma US Inc | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $13 |
How this compares
$2,718 in reported general payments places this provider in the 85th percentile of 3,328 nurse practitioner providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RybelsusSemaglutide | 12 | $16,226 |
| OzempicSemaglutide | 11 | $16,015 |
| MounjaroTirzepatide | 14 | $13,941 |
| Atorvastatin Calcium | 75 | $459 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 13 | $410 |
| Lisinopril | 48 | $386 |
| Amlodipine Besylate | 48 | $333 |
| Levothyroxine Sodium | 35 | $318 |
| Rosuvastatin Calcium | 20 | $291 |
| Omeprazole | 29 | $252 |
| Metoprolol Succinate | 15 | $250 |
| Losartan Potassium | 29 | $246 |
| Alendronate Sodium | 15 | $210 |
| Triamterene-HydrochlorothiazidTriamterene/Hydrochlorothiazid | 14 | $150 |
| Hydrochlorothiazide | 27 | $139 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $394 | $32,24123 claims |
| Lilly USA, LLCMounjaro | $451 | $13,94114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,328 nurse practitioner providers in Georgia.
Other nurse practitioner in Conyers
- Crystal LogsdonSavannah$566K
- Victor CzerkasijDalton$505K
- Kennon Mc CollumStockbridge$364K
- Pamela AllenRome$270K
- Tajuana BradleyJohns Creek$256K
- Janice McAlisterAtlanta$241K
- Jessica AdkinsSavannah$226K
- Laura ElledgeAtlanta$177K
- Afsha HussainiKennesaw$122K
- Elizabeth TyeAlbany$78K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.